0001103021-22-000017.txt : 20220131 0001103021-22-000017.hdr.sgml : 20220131 20220131175740 ACCESSION NUMBER: 0001103021-22-000017 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220127 FILED AS OF DATE: 20220131 DATE AS OF CHANGE: 20220131 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vollins James CENTRAL INDEX KEY: 0001757833 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31361 FILM NUMBER: 22575743 MAIL ADDRESS: STREET 1: C/O BIODELIVERY SCIENCES INTERNATIONAL STREET 2: 4131 PARK LAKE AVE SUITE 225 CITY: RALEIGH STATE: NC ZIP: 27607 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC CENTRAL INDEX KEY: 0001103021 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 352089858 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4131 PARKLAKE AVENUE STREET 2: SUITE 225 CITY: RALEIGH STATE: NC ZIP: 27612 BUSINESS PHONE: 919 582 9050 MAIL ADDRESS: STREET 1: 4131 PARKLAKE AVENUE STREET 2: SUITE 225 CITY: RALEIGH STATE: NC ZIP: 27612 FORMER COMPANY: FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP DATE OF NAME CHANGE: 20000111 4 1 wf-form4_164366984558819.xml FORM 4 X0306 4 2022-01-27 0 0001103021 BIODELIVERY SCIENCES INTERNATIONAL INC BDSI 0001757833 Vollins James C/O BIODELIVERY SCIENCES INTL, INC. 4131 PARKLAKE AVE. SUITE 225 RALEIGH NC 27612 0 1 0 0 See Remarks Common Stock 2022-01-27 4 M 0 16276 0 A 16276 D Common Stock 2022-01-31 4 M 0 8303 0 A 24579 D Common Stock 2022-01-31 4 M 0 3834 0 A 28413 D Stock Options (right to buy) 3.66 2022-01-27 4 A 0 282055 0 A 2032-01-26 Common Stock 282055.0 282055 D Restricted Stock Units 0.0 2022-01-27 4 A 0 50546 0 A 2025-01-27 Common Stock 50546.0 50546 D Restricted Stock Units 0.0 2022-01-27 4 M 0 16276 0 D 2024-01-27 Common Stock 16276.0 32552 D Restricted Stock Units 0.0 2022-01-29 4 M 0 8303 0 D 2023-01-29 Common Stock 8303.0 8303 D Restricted Stock Units 0.0 2022-01-31 4 M 0 3834 0 D 2022-01-31 Common Stock 3834.0 0 D The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2022. The stock options were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025. The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 27, 2021, under the Plan. The remaining RSUs vest in equal portions on: (i) January 27, 2023; and (ii) January 27, 2024. The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 29, 2020, under the Issuer's 2019 Plan. The remaining RSUs vest on January 29, 2023. The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 31, 2019, under the Issuer's 2011 Equity Incentive Plan, as amended. General Counsel, Chief Compliance Officer & Corporate Secretary /s/ James Vollins 2022-01-31